TH8957B - Inhibition of rejection of tissue transplants of connective tissue of the same subspecies. And the next planting part of different varieties But harmonious - Google Patents

Abstract

Cyclospirin A or other compounds which have the same reaction as cyclosporin A and the cobra venom factor. or other complement inhibitors can be used in tandem with each other. In order to enhance the succession parts of members of the same variety and the succession parts of members of different cultivars but that harmony survives and in order to help the next planting part Such a reaction from the transplanted tissue is not accepted.

Claims (1)

1. The use of a complement inhibitor and a cyclosporin A-like inhibitor in the preparation of a single or multiple agents for tissue implantation of a member of the same strain, or Planting parts of tissues of different species but harmoniously to survive or To assist from rejection of tissue implantation where connective tissue implants of members of the same species survive or aid from rejection reaction, implant tissue is implanted in the tissue of members of the same species. The same variety which is not cheap Acute rejection 2. The use of a complement inhibitor in the preparation of one or more drugs. For the subsection of tissues of members of the same variety or tissue implantation of different but harmonious members for survival or for assisted by tissue rejection reaction in the transplant recipient. The implantation of tissue treated with cyclosprine A-like immunosuppressant, in which the implantation of tissue of members of the same species survives or is assisted by an intolerance reaction. The implantation of tissues of a member of the same species, which is not acutely rejected, 3. Use as specified in claim 1 or No. 2, where the complement inhibitor is classical, A and alternate activation of the component 4. Use as specified in any of the Claims 1 to 3, where the component suppressor will consist of an MCP, DAF or C3 anti-agent 5. Use as defined in any of Claims 1 to 4, where the component inhibitor is composed of molecules that form a solid complex group with a factor. Bb where group oriented 6. Use as specified in any of the claims 1 to 3, where the component inhibitor contains toxic factors. Cobra 7. Use as set out in any of Claims 1 to 6, where cyclospyrin A-like immune will be cyclosporin or icosanoide 8. Use as set out in claim 7, where the immunosuppressive agent is cyclosponic A 9. Use as stated in claim 7 where the immunosuppressive agent is FK 506 1 0. Use as specified in any of Claim 1 to 9, where inhibitors, compost and immunosuppressants with cyclosporin-like reactions A is used for handling at the same time. Separate manipulation or sequential arrangement 1 1. Use as specified in any of Claim 1 to 10, where inhibitors, components and immunosuppressants reacting like cyclosporin A are to be classified. Set